ClinicalTrials.gg
CompletedNCT00002339Updated Jun 24, 2005

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

A Phase 3 interventional study of Fluconazole in Candidiasis, Esophageal and HIV Infections, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 13 Years to 70 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Ages
13 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fluconazole in Candidiasis — 1 open to participants now, 1 under way, none of them phase 3. Fluconazole · Candidiasis.

Enrollment
10th of 16
100 · median 228
Phase 3
5 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
4 of 19
Pfizer

Among the 19 studies testing fluconazole in Candidiasis, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 5 in phase 3, and was the 1st registered.

Candidiasis

132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.

Browse Candidiasis studies →

Open to participants now

1 of the 19 studies testing fluconazole in Candidiasis is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About fluconazole

Fluconazole: first FDA approval 1990 (DIFLUCAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 13 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing fluconazole in Candidiasis, or all of them as a file.
02

Study summary

To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.

Read the detailed description

Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8 weeks. Patients are evaluated weekly, and treatment continues for 2 weeks after resolution of symptoms. Endoscopic exams and possibly biopsies are performed at baseline and at the end of treatment. Patients undergo follow-up at 2 weeks post-treatment.

03

Conditions studied

  • Candidiasis, Esophageal
  • HIV Infections

Keywords

  • Esophagitis
  • Fluconazole
  • Acquired Immunodeficiency Syndrome
  • Candidiasis
  • Immunocompromised Host
04

Who can participate

Ages eligible
13 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • AIDS or other immunocompromising condition.
  • Candidal esophagitis.
  • of at least 2 months.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Evidence of non-candidal systemic fungal infection.
  • Abnormalities that may preclude esophagoscopy or endoscopy.
  • Unable to tolerate fluconazole.
  • Unable to give .
  • Enrollment in other experimental trials of approved or non-approved drugs or systemic compounds (unless approved by the Pfizer Clinical Monitor).
  • Other condition that would make patient unsuitable for enrollment.

Concurrent Medication:

Excluded:

  • Concomitant oral or topical antifungal agent.
  • Other experimental medications.

Patients with the following prior condition are excluded:

History of allergy to imidazoles or azoles.

Prior Medication:

Excluded:

  • Any oral or topical antifungal therapy within the past 3 days. Active use of illicit or illegal drugs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
100 participants

Interventions

06

Study locations

2 sites
  • Los Angeles County - USC Med Ctr
    Los Angeles, California 90033, United States
  • Houston Veterans Administration Med Ctr
    Houston, Texas 77030, United States
07

References and documents

Publications

  • Agresti MG, de Bernardis F, Mondello F, Bellocco R, Carosi GP, Caputo RM, Milazzo F, Chiodo F, Giannini V, Minoli L, et al. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. Eur J Epidemiol. 1994 Feb;10(1):17-22. doi: 10.1007/BF01717446. PubMed 7957784 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002339
Lead sponsor
Pfizer
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion